Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity131I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 7, 2013, Pages 2693-2700

  Molinaro, Eleonora ^a   Giani, Carlotta ^a   Agate, Laura ^a   Biagini, Agnese ^a   Pieruzzi, Letizia ^a   Bianchi, Francesca ^a   Brozzi, Federica ^a   Ceccarelli, Claudia ^a   Viola, David ^a   Piaggi, Paolo ^a   Vitti, Paolo ^a   Pacini, Furio ^b   Elisei, Rossella ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; LEVOTHYROXINE SODIUM; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROID HORMONE; THYROTROPIN;

ADOLESCENT; ADULT; ARTICLE; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CLINICAL EVALUATION; CLINICAL FEATURE; DIFFERENTIATED THYROID CANCER; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG EFFECT; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT CANCER; THYROGLOBULIN BLOOD LEVEL; THYROIDECTOMY; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TUMOR ABLATION;

ADULT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREMEDICATION; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RECOMBINANT PROTEINS; REMISSION INDUCTION; THYROGLOBULIN; THYROID GLAND; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; THYROXINE;

EID: 84879925437     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-4137     Document Type: Article

References (35)

1. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297-306. (Pubitemid 28065257)
2. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89:3668-3676. (Pubitemid 39089119)
3. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447-1463. (Pubitemid 32374886)
4. Schlumberger M, Berg G, Cohen O, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol. 2004;150:105-112. (Pubitemid 38312801)
5. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91:926-932. (Pubitemid 43357760)
6. Robbins RJ, Larson SM, Sinha N, et al. Aretrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med. 2002;43:1482-1488. (Pubitemid 35285874)
7. Robbins RJ, Tuttle RM, Sonenberg M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid. 2001;11:865-869. (Pubitemid 32847944)
8. Barbaro D, Boni G, Meucci G, et al. Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of postsurgical thyroid remnants. Nucl Med Commun. 2006;27:627-632. (Pubitemid 44305303)
9. Kukulska A, Krajewska J, Gawkowska-Suwinska M, et al. Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi. Thyroid Res. 2010;3:9.
10. Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA. 131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. J Clin Endocrinol Metab. 2007;92:28-38. (Pubitemid 46075005)
11. Pacini F, Castagna MG, Brilli L, Pentheroudakis G. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl. 5):v214-v219.
12. Pilli T, Brianzoni E, Capoccetti F, et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab. 2007;92:3542-3546. (Pubitemid 47435333)
13. Rosario PW, Xavier AC. Recombinant human thyroid stimulating hormone in thyroid remnant ablation with 1.1 GBq 131iodine in low-risk patients. Am J Clin Oncol. 2012;35:101-104.
14. 131I is associated with lowered radiotoxicity. J Nucl Med. 2008;49:1776-1782.
15. Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366:1663-1673.
16. Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366:1674-1685.
17. Elisei R, Schlumberger M, Driedger A, et al. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2009;94:4171-4179.
18. Tuttle RM, Brokhin M, Omry G, et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med. 2008;49:764-770. (Pubitemid 351717542)
19. Rosario PW, Mineiro Filho AF, Lacerda RX, Calsolari MR. Long-term follow-up of at least five years after recombinant human thyrotropin compared to levothyroxine withdrawal for thyroid remnant ablation with radioactive iodine. Thyroid. 2012;22:332-333.
20. Leung AM, Dave S, Lee SL, Campion FX, Garber JR, Pearce EN. Factors determining the persistence or recurrence of well-differentiated thyroid cancer treated by thyroidectomy and/or radioiodine in the Boston, MA area: a retrospective chart review. Thyroid Res. 2011;4:9.
21. Mazzaferri EL. Treating differentiated thyroid carcinoma: where do we draw the line? Mayo Clin Proc. 1991;66:105-111.
22. Mazzaferri EL. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid. 1997;7:265-271. (Pubitemid 27190594)
23. Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30 mCi 131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2002;87:4063-4068.
24. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71:414-424.
25. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer; Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
26. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787-803. (Pubitemid 43997716)
27. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561-577. (Pubitemid 23118304)
28. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32-35.
29. Wiseman SM, Loree TR, Rigual NR, et al. Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy. Head Neck. 2003;25:662-670. (Pubitemid 36909751)
30. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89:1638-1644. (Pubitemid 37464133)
31. Almeida JP, Sanabria AE, Lima EN, Kowalski LP. Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer. Head Neck. 2011;33:686-690.
32. Rosario PW, Calsolari MR. Salivary and lacrimal gland dysfunction after remnant ablation with radioiodine in patients with differentiated thyroid carcinoma prepared with recombinant human TSH. Thyroid. 2013;23(5):617-619.
33. 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:1440-1445.
34. Piccardo A, Arecco F, Morbelli S, et al. Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer. J Endocrinol Invest. 2010;33:83-87.
35. 131I ablation therapy in patients with differentiated thyroid cancer. J Nucl Med. 2004;45:988-994.